Background Increasing evidence shows that protection induced by acellular pertussis
vaccines is short-lived, requiring repeated booster vaccination to control pertussis disease …

Background: The transition from a whole-cell to a 5-component acellular pertussis vaccine
provided a unique opportunity to compare the effect that each type of vaccine had on the …

OBJECTIVE: Data on the effectiveness of the diphtheria–tetanus–acellular pertussis (DTaP)
vaccine in the first 4 years of life are sparse. We evaluated the vaccine effectiveness (VE) of …

Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …

Abstract Synopsis SB-3 (Infanrix™-DTPa 1) is one of a new generation of vaccines for
immunisation against pertussis (whooping cough), diphtheria and tetanus. It is a 3 …

Background In the United States, children receive five doses of diphtheria, tetanus, and
acellular pertussis (DTaP) vaccine before 7 years of age. The duration of protection after five …

OBJECTIVE: Vaccination with tetanus toxoid, reduced diphtheria toxoid, and acellular
pertussis (Tdap) is recommended for adults who have close contact with infants aged< 12 …

The aim of this assessor-blinded trial was to compare the immunogenicity and reactogenicity
of a candidate diphtheria, tetanus toxoids and acellular pertussis vaccine with reduced …

This Policy Statement was retired June 2012. The purpose of this statement is to provide the
rationale and recommendations for adolescent use of tetanus toxoid, reduced diphtheria …

This review offers a perspective on the acellular pertussis vaccine efficiency trials concluded
in the 1990s and presents the main conclusions of a meta-analysis of 52 studies that …